FLT3 inhibitor FF-10101 succinate
Term · Oncology and biomedicine · MLC-T-ONC-013627
The succinate salt form of FF-10101, a FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2) inhibitor, with potential antineoplastic activity. Upon administration of FLT3 inhibitor FF-10101 succinate (FF-10101-01), FF-10101 irreversibly binds to and inhibits the activity of FLT3. This inhibits the proliferation of FLT3-expressing cancer cells. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B-lineage neoplasms and in acute myeloid leukemias.
| Identifier | MLC-T-ONC-013627 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | FF-10101 succinate; FF10101 Succinate |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-013627",
"term": "FLT3 inhibitor FF-10101 succinate",
"field": "Oncology and biomedicine",
"definition": "The succinate salt form of FF-10101, a FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2) inhibitor, with potential antineoplastic activity. Upon administration of FLT3 inhibitor FF-10101 succinate (FF-10101-01), FF-10101 irreversibly binds to and inhibits the activity of FLT3. This inhibits the proliferation of FLT3-expressing cancer cells. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B-lineage neoplasms and in acute myeloid leukemias.",
"synonyms": [
"FF-10101 succinate",
"FF10101 Succinate"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/flt3-inhibitor-ff-10101-succinate/"
}
Record 7,361 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.